ELI LILLY & Co (LLY)

Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines worldwide, with products sold in approximately 90 countries and manufacturing facilities across the U.S. (including Puerto Rico), Europe, and Asia. The company's portfolio spans four core therapeutic areas: Cardiometabolic Health (including Jardiance, Mounjaro, Trulicity, Zepbound, Basaglar, Humalog, and Humulin insulin products for diabetes and related cardiovascular/renal conditions), Oncology (including Verzenio, Cyramza, Erbitux, Jaypirca, Retevmo, Inluriyo, and Tyvyt for various cancers), Immunology (including Taltz, Omvoh, Olumiant, and Ebglyss for autoimmune and inflammatory conditions), and Neuroscience (including Emgality for migraine and Kisunla for Alzheimer's disease). Several products are marketed through collaborations with partners such as Boehringer Ingelheim, Innovent Biologics, Incyte Corporation, and Almirall S.A. Lilly distributes products in the U.S. primarily through major wholesalers—McKesson, Cencora, and Cardinal Health, each representing significant revenue concentration—while also expanding direct-to-patient access via its LillyDirect digital platform; internationally, it relies on its own sales organizations and third-party distribution and promotion arrangements.

The company faces intense global competition from branded, generic, and biosimilar products, as well as increasing competition from China and other markets with expanding R&D capabilities, and it must navigate complex U.S. private-sector dynamics involving consolidated payers, formulary restrictions, and rebate negotiations that pressure pricing and access, particularly for its significant anti-obesity medicine revenues. Intellectual property protection—through compound patents, data protection, patent term extensions, and orphan/pediatric exclusivities—is critical to sustaining exclusivity for key products, with estimated patent and data protection expiry dates extending into the 2020s and 2030s for major products across all therapeutic areas; the company also has late-stage pipeline candidates such as insulin efsitora alfa and orforglipron under regulatory review in the U.S., EU, and Japan for diabetes and obesity indications.